Marker Therapeutics, Inc.
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
MRKR | US
Overview
Corporate Details
- ISIN(s):
- US57055L1070 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 2450 HOLCOMBE BLVD, 77021 HOUSTON
- Website:
- https://markertherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation, non-genetically modified T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology, Multi-Antigen Recognizing (MAR) T cells, expands a patient's natural T cells to recognize and eliminate tumors expressing multiple antigens. This approach aims to provide durable anti-tumor responses with a favorable safety profile compared to genetically engineered cell therapies. The technology was developed at Baylor College of Medicine. Its lead product candidate, MT-601, is being evaluated in a Phase 1 study for lymphoma patients who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Marker Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Marker Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Marker Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
